Can-Fite BioPharma

Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 finance.yahoo.com/sectors/health… $CANF

Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient finance.yahoo.com/sectors/health… $canf

Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance finance.yahoo.com/news/fite-expa… $CANF

Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study ir.canfite.com/news-events/pr… $CANF

Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson finance.yahoo.com/news/fite-anno… $CANF

Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson finance.yahoo.com/news/fite-pati… $CABF

Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson finance.yahoo.com/news/fite-comp… $CANF

Can-Fite Provides Update on Clinical and Financial Status ir.canfite.com/news-events/pr… $CANF

Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson finance.yahoo.com/news/fite-9-su… $CANF

Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia finance.yahoo.com/news/breakthro… $CANF

Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston finance.yahoo.com/news/fite-pres… $CANF

Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis finance.yahoo.com/news/fite-rais… $CANF

Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships finance.yahoo.com/news/fite-gene… $CANF

Can-Fite Reports 2024 Financial Results and Clinical Update finance.yahoo.com/news/fite-repo… $CANF

Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol finance.yahoo.com/news/fite-init… $CANF

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson finance.yahoo.com/news/fite-init… $CANF

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson ir.canfite.com/news-events/pr… $CANF

Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient finance.yahoo.com/news/fite-fda-… $CANF

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits finance.yahoo.com/news/fite-inno… $canf

Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson finance.yahoo.com/news/disappear… $CANF